Urethral carcinomas most frequently harbor alterations in TP53, FGFR3, PIK3CA, KDM6A, and CDKN2A .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, FGFR3 Mutation, and PIK3CA Mutation are the most common alterations in urethral carcinoma .
There are 7 clinical trials for urethral carcinoma, of which 6 are open and 1 is completed or closed. Of the trials that contain urethral carcinoma as an inclusion criterion, 3 are phase 1 (2 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open).
Atezolizumab, nivolumab, and placebo are the most common interventions in urethral carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.